| A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06687234 AS ADD-ON THERAPY TO INFLIXIMAB IN ACTIVE ULCERATIVE COLITIS SUBJECTS WHO ARE NOT IN REMISSION (BUILD UC) |
Completed |
PF-06687234 |
2a |
B7581002 |
NGHA-R |
| "A PHASE 2/3, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A" |
Terminated |
ALXN1101( Cyclic pyranopterin monophosphate monohydrobromide dihydrate) |
2/3 |
ALXN1101-MCD-202 |
KFMC |
| A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma |
Completed |
QAW039/Fevipiprant |
3 |
CQAW039A2316 |
KFMC |
| Use of high dose of Colistin in Multidrug Resistant Gram Negative infections. Randomized Controlled clinical Trial |
Completed |
Colistin |
4 |
KSMC-12-13 |
King Saud Medical City |
| "AN OBSERVATIONAL, NON-INTERVENTIONAL,MULTI-CENTER, MULTI-NATIONAL STUDY OFPATIENTS WITH ATYPICAL HEMOLYTIC-UREMICSYNDROME(AHUS REGISTRY)" |
Rejected |
- |
4 |
M11-001 |
N/A |
| "easypod connect: A regional, Multicentre, Observational study to evaluate Adherenceand Long Term Outcomes of Therapy in Paediatric subjects using “easypodTM” electromechanical device for growth hormone treatment" |
Rejected |
- |
4 |
200104-534 |
King Khalid University Hospital (Riyadh) |
| "An Open-label, Multicentre, Randomised, 2-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Pregnant Women" |
Terminated |
Ferrous Sulphate + Ferinject |
3 |
FER-ASAP-2009-01 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase IV Double-Blind Placebo-Controlled Randomized Clinical Trial Assessing the Effect of 2 month consumption of Vetal Laban Including Lactobacillus acidophilus NCFM on Functional Gastrointestinal Symptoms Among Subjects Fulfilling Rome III Criteria for A Phase IV, Randomized, double-blind, placebo-controlled study with parallel groups Irritable Bowel Syndrome |
Rejected |
Vetal Laban containing Lactobacillus acidophilus NCFM at 1.6 x 109 CFU per container |
4 |
IBS - 0920 |
King Fahad Medical City (Riyadh) |
| The Effectiveness of Convalescent Plasma for the Treatment of Severe COVID-19 Cases in Intensive Care Unit |
Ongoing |
Convalescent Plasma |
3 |
IRB 2020-19-V2 |
King Faisal Specialist Hospital and Research Center (Jeddah) |
| An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Loxtra Eye Drops Containing Ofloxacin (3 mg), Prednisolone (2 mg) and Tetrahydrozoline Hydrochloride (0.4 mg) in Subjects with Bacterial Conjunctivitis and Other Ocular Inflammatory Conditions |
Completed |
Loxtra |
4 |
LOX001 |
King Khalid University Hospital (Riyadh) |
